Bright Minds Biosciences Inc. reported CAD 1.5M of revenue over the trailing twelve months, +4943% on the year before. 6 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: CAD 1.5M (to FY2025). Net income: −CAD 12M, trailing twelve months to FY2025. EPS: −CAD 1.78, trailing twelve months to FY2025.

DRUGBright Minds Biosciences Inc.

Healthcare

$52.39-16% 1Y

$52.39

$48.0952 weeks$95.99

DRUG as reported

Bright Minds Biosciences Inc. reported CAD 1.5M of revenue over the trailing twelve months, +4943% on the year before. 6 reported series are charted on this page, each one as filed.

CAD 1.5M

Revenue, trailing twelve months · to FY2025 · +4943% against the twelve months before

Net income: −CAD 12M
Net income · +336% year on year · trailing twelve months to FY2025
EPS: −CAD 1.78
EPS · +174% year on year · trailing twelve months to FY2025

Details›

Every series Ryufin has for DRUG, trailing twelve months
Series	Latest	Year on year	As of
Revenue	CAD 1.5M	+4943%	FY2025
Net income	−CAD 12M	+336%	FY2025
EPS	−CAD 1.78	+174%	FY2025
Net margin	−805%	n/a	FY2025
ROE	−15%	n/a	FY2025
ROA	−14%	n/a	FY2025

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.